Microba Commences Phase I Clinical Trial for IBD Therapeutic
First participants have been successfully dosed in a Phase I Clinical Trial of MAP 315, Microba’s lead Therapeutic Program in Inflammatory Bowel Disease. MAP 315, is a novel live biotherapeutic product being developed for the treatment of ulcerative colitis an


